Pharmaceutical

J&Js Lazcluze/Rybrevant combination obtains European approval to treat NSCLC 

The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-of-care Tagrisso in non-small cell lung cancer (NSCLC).

Jan 22, 2025 - 06:00
J&Js Lazcluze/Rybrevant combination obtains European approval to treat NSCLC 
The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-of-care Tagrisso in non-small cell lung cancer (NSCLC).
Read the original article

Tags:

Previous Article

Key Lead Generation Providers and Technology Solutions for the Pharmaceutical In...

Next Article

Junshi partners LEO Pharma for toripalimab distribution in Europe

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Vinod Khosla’s bold AI prediction, digital therapeutics trial updates, & funding for AI in pharma

STAT+: Vinod Khosla’s bold AI prediction, digital thera...

May 7, 2023

AbbVie reports 9.7% fall in global net revenues for Q1 2023

AbbVie reports 9.7% fall in global net revenues for Q1 ...

Apr 28, 2023

New chronic Covid study offers insight into which immunocompromised patients are most at risk

New chronic Covid study offers insight into which immun...

Jan 24, 2024